Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cytosorbents Corporation (CTSO) Fair Value & Analysis

Healthcare · US · Market cap $27.5M

Price$0.4290
Fair Value$0.4200
Upside-2.1%
Quality95/100
Evidence: Low Range $0.3200 – $0.5300

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cytosorbents Corporation (CTSO) currently trades at $0.4290, while our model-based Fair Value estimate is $0.4200 — implying the stock looks roughly 2.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock,…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Cytosorbents Corporation (CTSO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.4200 versus a price of $0.4290 — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CTSO?
Our 21-model fair value for Cytosorbents Corporation is $0.4200 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.4290.
What is the quality score of CTSO?
Cytosorbents Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.